Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SRRK
SCHOLAR ROCK HOLDING CORPORATION
NASDAQ
$57.80
▼ DOWN 2.46% (-1.46)

KEY STATISTICS

Market Cap$6.93 B
52w High$61.76
52w Low$27.07
Dividend Yield—
Frequency—
P/E-16.75
Volume809.72K
Shares Out.119.83M

COMPANY

LEADERSHIP

David L. Hallal
CHIEF EXECUTIVE
David L. Hallal

COMPENSATION 2026

Salary$637,500
Stock Awards$22,518,500
Incentive Plan Pay$452,293
All Other Comp.$67,646
Total$33,300,927

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 25, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
289

PRICE TARGET

Target High$76.00
Target Low$55.00
Target Median$62.00
Target Consensus$62.14

UPCOMING EARNINGS

DateNov 13, 2026
DayFriday
Rev. Est.$75.00K
NOV
13
FRI

PRICE

$57.80 ▼ DOWN 2.46% (−$1.46)
$57.75$58.50$59.259:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM57.80

About Scholar Rock Holding Corporation

https://scholarrock.com ↗

Scholar Rock is a biopharma company developing medicines targeting protein growth factor signaling for serious diseases, with candidates like Apitegromab and SRK-181 in clinical trials, and collaborations with Gilead.

INDUSTRY

Biotechnology

A PRODUCT SCHOLAR ROCK HOLDING CORPORATION IS KNOWN FOR

Apitegromab
Apitegromab

Apitegromab, Scholar Rock's investigational muscle-targeted therapy for SMA, is a selective myostatin inhibitor expected to resubmit for approval in 2026 with a potential U.S. launch.

COMPETITORS

COMPETITOR
BHVN COMPARE
BIIB COMPARE
NVS COMPARE
PTCT COMPARE
SRPT COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
148
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.01% · 3.4M
IWM
0.20% · 2.8M
XBI
1.19% · 2.4M
SCHA
0.12% · 472.9K
TMSL
0.36% · 185.5K
XRSG.L
0.21% · 103.6K
LABU
0.81% · 87.3K
FBCG
0.06% · 72.9K
RSSL
0.20% · 53.4K
PRFZ
0.06% · 27.2K
BBSC
0.20% · 25.2K
BBC
0.80% · 7.1K
MMSC
0.70% · 6.2K
HRTS
0.64% · 6.2K
THNR
5.72% · 5.3K
URTY
0.08% · 4.5K
ACSG
0.50% · 4.4K
SGRW
0.80% · 4.0K
STXK
0.26% · 3.9K
TILT
0.01% · 3.4K
BKSE
0.21% · 3.2K
RFLR
0.17% · 2.7K
RTWO.L
0.05% · 2.0K
ESSC
0.22% · 1.8K
VETS
0.25% · 1.6K
PCSG
1.32% · 587

INSTITUTIONAL OWNERSHIP

SHARES OWNED
78.00%
HOLDERS
390
TOP 12 OF 390 · RANKED BY POSITION SIZE
Fmr LLC
18.0M sh · $989.74M
Siren, L.L.C.
10.8M sh · $476.84M
Blackrock, Inc.
9.5M sh · $522.17M
Redmile Group, LLC
9.1M sh · $445.72M
Samsara Biocapital, LLC
6.9M sh · $379.37M
Price T Rowe Associates Inc /Md/
6.9M sh · $256.33M
Wellington Management Group Llp
6.7M sh · $369.99M
Orbis Allan Gray Ltd
5.9M sh · $326.34M
Blackrock Inc.
5.7M sh · $47.18M
Vanguard Group Inc
5.2M sh · $228.86M
State Street Corp
4.7M sh · $260.08M
Bellevue Group AG
4.1M sh · $178.69M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR
FLIER JEFFREY S.
Sale · 15 shares
2026-07-01
★
DIRECTOR
Burow Kristina
Sale · 948 shares
2026-07-01
★
DIRECTOR
Gilman Michael
Sale · 1.3K shares
2026-07-01
★
DIRECTOR
Gilman Michael
Sale · 1.2K shares
2026-07-01

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 3
BUY 3
OUTPERFORM 2
8 GRADES IN THE LAST 12 MONTHS
JP Morgan OVERWEIGHT Wedbush OUTPERFORM HC Wainwright & Co. BUY Citigroup BUY Barclays OVERWEIGHT BMO Capital OUTPERFORM Piper Sandler OVERWEIGHT Truist Securities BUY

SECTORS PEERS

PEERPRICE
KNSA$78.08COMPARE
XENE$59.99COMPARE
ADPT$25.19COMPARE
IDYA$40.11COMPARE
LEGN$19.88COMPARE
IRON$80.03COMPARE
BEAM$29.32COMPARE
ZLAB$26.08COMPARE